Search results for " bronchiectasis"

showing 6 items of 6 documents

Extensive molecular analysis of patients bearing CFTR-related disorders.

2012

Cystic fibrosis transmembrane conductance regulator (CFTR)–related disorders (CFTR-RDs) may present with pancreatic sufficiency, normal sweat test results, and better outcome. The detection rate of mutations is lower in CFTR-RD than in classic CF: mutations may be located in genes encoding proteins that interact with CFTR or support channel activity. We tested the whole CFTR coding regions in 99 CFTR-RD patients, looking for gene mutations in solute carrier (SLC) 26A and in epithelial Na channel (ENaC) in 33 patients who had unidentified mutations. CFTR analysis revealed 28 mutations, some of which are rare. Of these mutations, RT-PCR demonstrated that the novel 1525-1delG impairs exon 10 s…

Epithelial sodium channelcongenital hereditary and neonatal diseases and abnormalitiesCystic fibrosis CFTR SLC26A SCNNCystic FibrosisAnion Transport ProteinsDNA Mutational Analysismolecular analysiCystic Fibrosis Transmembrane Conductance RegulatorGene mutationPathology and Forensic Medicinecongenital bilateral absence of vasa deferentesExonGene Frequencydisseminated bronchiectasiscongenital bilateral absence of vasa deferenteHumansTrypsinmolecular analysisEpithelial Sodium ChannelsGeneCells CulturedGenetic Association StudiesGeneticsbiologydisseminated bronchiectasiEpithelial Cellsrespiratory systemrecurrent pancreatitidigestive system diseasesCystic fibrosis transmembrane conductance regulatorrespiratory tract diseasesSolute carrier familyCFTR related disordersTrypsin Inhibitor Kazal PancreaticCase-Control StudiesRNA splicingMutationbiology.proteinMolecular MedicineCFTR related disorderSLC26 familyCarrier ProteinsNa channel ENaCMinigenerecurrent pancreatitis
researchProduct

High Flow Nasal Therapy Use in Patients with Acute Exacerbation of COPD and Bronchiectasis: A Feasibility Study

2020

The efficacy and feasibility of high flow nasal therapy (HFNT) use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and bronchiectasis is unknown. We performed a single-center, single-arm prospective observational study in patients with AECOPD, documented bronchiectasis, pH >= 7.35, respiratory rate (RR) >= 26 breaths/minute despite receiving maximal medical treatment and oxygen via face mask up to 10 L/m. Patients received HFNT (Airvo 2, Fisher & Paykel) at a gas flow of 50 L/min and FIO2 adjusted to maintain SpO(2) >= 92%. Dyspnea, rated by Borg scale, RR, arterial blood gases and mucus production (ranging from 1 to 3) were collected befor…

Pulmonary and Respiratory MedicineMaleAcute exacerbation of chronic obstructive pulmonary diseasemedicine.medical_specialtyExacerbationbronchiectasishumidification03 medical and health sciencesPulmonary Disease Chronic Obstructivebronchiectasi0302 clinical medicineacute respiratory failure bronchiectasis COPD High flow nasal cannula humidification mucus plug sputumRespiratory RateInternal medicineMedicineCannulaHumansCOPDIn patientAcute respiratory failure030212 general & internal medicineProspective StudiesAgedCOPDBronchiectasisacute respiratory failurebusiness.industryOxygen Inhalation TherapysputumCarbon Dioxidemedicine.diseaseSymptom Flare UpHigh flow nasal cannulaMucusDyspnea030228 respiratory systemmucus plugSputumFeasibility StudiesFemalemedicine.symptomBlood Gas AnalysisbusinessHigh flow
researchProduct

Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study

2022

High-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE). Methods: This is a retrospective bicentric case-control study of outpatients with BE on optimized medical treatment with a severe exacerbation requiring hospitalization in the previous year. Patients on long-term home HFNT (cases) and patients on optimized medical treatment alone (controls) were matched by age, sex, bronchiectasis severity index, and exacerbations in the previous year. Data on BE exacerbations, hospitalizations/year, mucus features, respiratory symptoms, and pulmonary func…

bronchiectasis; exacerbation; high-flow nasal cannula; high-flow nasal therapy; hospitalization; mucus;exacerbationbronchiectasis; exacerbation; high-flow nasal cannula; high-flow nasal therapy; hospitalization; mucushigh-flow nasal cannulahigh-flow nasal cannula; high-flow nasal therapy; bronchiectasis; mucus; exacerbation; hospitalizationbronchiectasismucusSettore MED/10 - Malattie dell'Apparato Respiratoriohigh-flow nasal therapyGeneral Medicinehospitalization
researchProduct

The Severe Asthma Network in Italy: Findings and Perspectives

2019

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by accredited centers on severe asthma. Objective To analyze epidemiological, clinical, inflammatory, functional, and treatment characteristics of severe asthmatics from the SANI registry. Methods All consecutive patients with severe asthma were included into the registry, without exclusion criteria to have real-life data on demographics, asthma control, treatments (including biologics), inflammatory biomarkers, and comorbidities. Results A total of 437 patients (mean age: 54.1 years, 57.2% females, 70.7% atopics, 94.5% in Global Initiative for Asthma severity step V) were enrolled into the study. The mean …

AdultMalemedicine.medical_specialtyRegistrySevere asthmaExacerbationBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Immunology and AllergyOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioComorbiditiesAtopy03 medical and health sciencesBronchiectasi0302 clinical medicineFood allergyInternal medicineLate-onset asthmaNasal polypsBronchiectasis; Comorbidities; Late-onset asthma; Nasal polyps; Registry; SANI; Severe asthma; Adult; Aged; Asthma; Bronchiectasis; Comorbidity; Eosinophils; Female; Humans; Immunoglobulin E; Italy; Male; Middle Aged; Nasal Polyps; Registries; RhinitisMedicineHumansBronchiectasis Comorbidities Late-onset asthma Nasal polyps Registry SANI Severe asthma Immunology and AllergyImmunology and Allergy030212 general & internal medicineRegistriesAsthmaAgedRhinitisBronchiectasisbusiness.industryNasal polypSANIImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaBronchiectasisEosinophils030228 respiratory systemItalyAsthma Control QuestionnaireFemaleComorbiditiebusinessMepolizumabmedicine.drug
researchProduct

Carga y factores de riesgo para la neumonía adquirida en la comunidad de Pseudomonas aeruginosa : un estudio multinacional de prevalencia puntual de …

2018

Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeru…

Pneumonia Pseudomonas aeruginosaMaleantibiotic resistanceInternationalityCross-sectional studybacterial colonizationvery elderlyPrevalenceDrug ResistanceDrug resistancePneumònia adquirida a la comunitatPseudomonas aeruginosa community acquired pneumoniaPulmonary Disease Chronic Obstructive0302 clinical medicineTracheostomyCommunity-acquired pneumoniaRisk FactorsEpidemiology80 and overPrevalenceMedicineCommunity-Acquired Infection030212 general & internal medicineAged 80 and overCross InfectionadultarticleBacterialMiddle AgedAntibiotic coverageBronchiectasisCommunity-Acquired Infectionshospital patientpriority journalrisk factorAged; Aged 80 and over; Bronchiectasis; Community-Acquired Infections; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Female; Humans; Internationality; Logistic Models; Male; Middle Aged; Pneumonia Bacterial; Prevalence; Pseudomonas aeruginosa; Pulmonary Disease Chronic Obstructive; Risk Factors; TracheostomyPseudomonas aeruginosaInfectious diseasesFemaleHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveCommunity-acquired pneumoniaLogistic ModelAdmissionSettore MED/10 - Malattie Dell'Apparato Respiratoriochronic lung diseasePulmonary Disease03 medical and health sciencesBronchiectasiInternal medicinePseudomonasDrug Resistance BacterialPneumonia BacterialHumanscontrolled studyhumanAgedCross-Sectional StudieBronchiectasisbusiness.industryRisk Factorcommunity acquired pneumoniaPneumoniamedicine.diseaselogistic regression analysismajor clinical studyantibiotic sensitivityPneumoniahospital admissionCross-Sectional StudiesLogistic Models030228 respiratory systemmicrobiological examinationbusinesschronic obstructive lung disease
researchProduct

Bronchiectasis In Metaphyseal Acroscyphodysplasia With Cone-Shaped Epiphyses (Bellini Disease): A Five Years Follow Up

2013

We present an adolescent with Metaphyseal acroscyphodysplasia (Bellini disease), characterized by severe short stature with accelerated bone maturation, micromelia predominating in the lower limbs, knee flexion, severe brachydactyly, very short hands and feet, metaphyseal changes and specific radiologic features, cup-shaped distal femoral metaphysis with cone-shaped epiphyses, short hands and feet, dental malocclusion. She presented chronic respiratory infections, with secondary bronchiectasis in the course of the follow up. This is the first case reported in literature of a patient with this extremely rare metaphyseal dysplasia, the Bellini disease, associated with bronchiectasis.

Settore MED/38 - Pediatria Generale E SpecialisticaBellini disease Bronchiectasis Metaphyseal Acroscyphodysplasia
researchProduct